IL143733A0 - Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy - Google Patents

Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy

Info

Publication number
IL143733A0
IL143733A0 IL14373399A IL14373399A IL143733A0 IL 143733 A0 IL143733 A0 IL 143733A0 IL 14373399 A IL14373399 A IL 14373399A IL 14373399 A IL14373399 A IL 14373399A IL 143733 A0 IL143733 A0 IL 143733A0
Authority
IL
Israel
Prior art keywords
gamma
narcolepsy
treatment
disclosed
formulations
Prior art date
Application number
IL14373399A
Other languages
English (en)
Original Assignee
Orphan Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22351244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL143733(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orphan Medical Inc filed Critical Orphan Medical Inc
Publication of IL143733A0 publication Critical patent/IL143733A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL14373399A 1998-12-23 1999-12-22 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy IL143733A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11374598P 1998-12-23 1998-12-23
PCT/US1999/030740 WO2000038672A2 (en) 1998-12-23 1999-12-22 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy

Publications (1)

Publication Number Publication Date
IL143733A0 true IL143733A0 (en) 2002-04-21

Family

ID=22351244

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14373399A IL143733A0 (en) 1998-12-23 1999-12-22 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
IL143733A IL143733A (en) 1998-12-23 2001-06-13 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL143733A IL143733A (en) 1998-12-23 2001-06-13 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy

Country Status (11)

Country Link
US (14) US6472431B2 (ja)
EP (1) EP1140061B1 (ja)
JP (2) JP4374441B2 (ja)
AT (1) ATE238783T1 (ja)
AU (1) AU779354B2 (ja)
CA (1) CA2355293C (ja)
DE (1) DE69907508T2 (ja)
DK (1) DK1140061T3 (ja)
ES (1) ES2193777T3 (ja)
IL (2) IL143733A0 (ja)
WO (1) WO2000038672A2 (ja)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038672A2 (en) * 1998-12-23 2000-07-06 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
DE10315640A1 (de) * 2003-04-04 2004-10-14 Ignatov, Konstantin Verfahren zur kontrollierten Freisetzung von Komponenten in eine Lösung
EP1629732A1 (en) * 2004-08-27 2006-03-01 Purac Biochem BV Composition for inactivating yeasts or molds in soft drinks
US20060069040A1 (en) * 2004-09-07 2006-03-30 Mortimer Mamelak GHB compositions
AU2005304352A1 (en) * 2004-11-10 2006-05-18 The Trustees Of Columbia University In The City Of New York Method for treatment of movement disorders
US7838556B2 (en) * 2006-02-21 2010-11-23 University Of Maryland, Baltimore Ethers of 3-hydroxyphenylacetic acid as selective gamma-hydroxybutyric acid receptor ligands
CA2650716C (en) * 2006-05-01 2014-06-17 Universiteit Gent Hydroxybutyrate and poly-hydroxybutyrate as components of animal feed or feed additives
BRPI0602825A2 (pt) * 2006-06-23 2012-04-24 Rhodia Br Ltda formulação de pó efervescente auto-refrigerante para bebidas e uso de formulação em pó efervescente
US8524944B2 (en) * 2008-04-15 2013-09-03 Norac Pharma Process for the preparation of sodium gamma-hydroxybutyrate
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8771735B2 (en) * 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
FR2938431B1 (fr) * 2008-11-14 2013-12-20 Debregeas Et Associes Pharma Nouvelle composition a base d'acide gamma-hydroxybutyrique
US8410304B2 (en) * 2009-04-15 2013-04-02 Norac Pharma Process for preparing gamma-hydroxybutyrate
FR2949061B1 (fr) 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
FR2949062B1 (fr) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
BR112012024019B1 (pt) 2010-03-24 2021-10-19 Jazz Phamaceuticals, Inc Forma de dosagem de liberação controlada para administração oral
EP2598137B1 (en) * 2010-07-29 2022-07-06 Ecolab USA Inc. Method of treating animal drinking water with interval dosing of a biocide
US20160068463A1 (en) 2012-11-14 2016-03-10 Metabolix, Inc. Production of salts of 4-hydroxybutyrate using biobased raw materials
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
WO2014096984A1 (en) * 2012-12-21 2014-06-26 Wockhardt Limited Stable pharmaceutical composition of sodium oxybate
WO2014127053A2 (en) 2013-02-13 2014-08-21 Metabolix, Inc. Process for ultra pure chemical production from biobased raw starting materials
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
US9801852B2 (en) * 2013-08-30 2017-10-31 Jazz Pharmaceuticals, Inc. Devices and methods for facilitating and controlling use of a medication
KR102245345B1 (ko) 2014-09-29 2021-04-28 조게닉스 인터내셔널 리미티드 의약품 배포 제어를 위한 제어 시스템
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US9750811B2 (en) 2015-09-15 2017-09-05 Boveda, Inc. Devices and methods for controlling headspace humidity and oxygen levels
CN108283000B (zh) 2015-09-23 2021-04-13 凯瑞康宁生物工程（武汉）有限公司 γ-羟基丁酸的前药及其组合物和用途
EP3393470B1 (en) 2015-12-22 2021-01-20 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
DK3393655T3 (da) 2015-12-22 2021-03-15 Zogenix International Ltd Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11000498B2 (en) * 2016-07-22 2021-05-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
MX2019001799A (es) 2016-08-24 2019-06-13 Zogenix International Ltd Formulacion para inhibir la formacion de agonistas de 5-ht2b y metodos de utilizacion de la misma.
EP4364794A3 (en) 2016-09-06 2024-07-24 Axsome Malta Ltd. Solvate form of (r)-2-amino-3-phenylpropyl carbamate
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
JP7074750B2 (ja) 2016-10-06 2022-05-24 ジャズ ファーマスティカルズ アイルランド リミテッド カルバモイルフェニルアラニノール化合物およびその使用
US12098015B2 (en) 2016-10-12 2024-09-24 Boveda Inc. Device for controlling headspace humidity and methods for making the same
CA3034514C (en) 2016-10-12 2019-06-18 Drug Plastics & Glass Company, Inc. Container and closure assembly with predetermined humidity and related method
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US20180303821A1 (en) * 2017-04-24 2018-10-25 BraneQuest, Inc. Membrane active molecules
AU2018278332B2 (en) 2017-06-02 2022-05-19 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
CN111094238B (zh) 2017-07-31 2023-06-09 杰资制药爱尔兰有限公司 氨基甲酰基苯丙氨醇类似物及其用途
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
CA3085941A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
US11337920B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
WO2019126218A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
KR20210094513A (ko) 2018-11-19 2021-07-29 재즈 파마슈티칼즈 아일랜드 리미티드 알코올-내성 약물 제형
GB201821066D0 (en) * 2018-12-21 2019-02-06 Univ Oxford Innovation Ltd Sleep modulation
JP7553453B2 (ja) 2019-03-01 2024-09-18 フラメル アイルランド リミテッド 食事摂取状態における改善された薬物動態を有するガンマ－ヒドロキシ酪酸塩組成物
TW202135790A (zh) 2019-12-24 2021-10-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 Ghb給藥
JP7514310B2 (ja) 2020-02-13 2024-07-10 中興通訊股▲ふん▼有限公司 ランダムアクセスプロシージャにおけるプリアンブルおよびペイロードメッセージの伝送
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
CN115666527A (zh) 2020-10-05 2023-01-31 凯瑞康宁生物工程有限公司 γ-羟基丁酸衍生物的修饰释放组合物
WO2022076824A1 (en) 2020-10-08 2022-04-14 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
TW202228666A (zh) 2020-10-16 2022-08-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 使用ghb之治療方法
JP2024511991A (ja) 2021-03-19 2024-03-18 エックスダブリューファーマ リミテッド ガンマ－ヒドロキシ酪酸誘導体の組み合わされた放出製剤の薬物動態
EP4415701A1 (en) 2021-10-11 2024-08-21 Jazz Pharmaceuticals Ireland Limited Method of administering oxybate
US20230118007A1 (en) * 2021-10-18 2023-04-20 Synovent Laboratories, LLC Medical devices and systems for use
WO2023135150A1 (en) 2022-01-11 2023-07-20 Jazz Pharmaceuticals Ireland Limited Method of administering oxybate
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2023178288A1 (en) 2022-03-17 2023-09-21 Azora Therapeutics, Inc. Companion diagnostics and strategies for treatment with an aryl hydrocarbon receptor agonist compound
WO2024163966A1 (en) 2023-02-03 2024-08-08 Tris Pharma, Inc. Low sodium oxybate once nightly composition

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3051619A (en) 1960-05-19 1962-08-28 Equilibre Biolog L 4-hydroxy butyric acid therapeutic compositions and process of use for clinical sedation, hypnosis, or anaesthesia
GB922029A (en) * 1960-05-19 1963-03-27 Equilibre Biolog L Therapeutic composition
US4183916A (en) 1978-03-31 1980-01-15 Beecham Inc. Oral compositions
US4374441A (en) * 1980-05-23 1983-02-22 Book Covers, Inc. Method of making a book cover and pocket element therefor
ZA814854B (en) 1980-07-17 1982-07-28 J Klosa Nonhygroscopic salts of 4-hydroxybutryric acid, methods of their production and pharmaceutical preparations containing these salts
EP0044801B1 (de) 1980-07-17 1984-02-15 Josef Dr. Klosa Nichthygroskopische Salze der 4-Hydroxybuttersäure, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Mittel
EP0235408B1 (en) 1984-08-06 1991-01-09 The University Of Toronto Innovations Foundation Pharmaceutical composition and treatment
US4738985A (en) 1986-03-19 1988-04-19 The University Of Toronto Innovations Foundations Pharmaceutical composition and treatment
US5210083A (en) 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
IT1217783B (it) * 1988-06-03 1990-03-30 Farmaceutico Ct S R L Lab Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative
IL93618A0 (en) 1989-03-06 1990-12-23 Lilly Co Eli Improved diluent formulation for daptomycin
JP2564690B2 (ja) 1990-06-14 1996-12-18 三省製薬 株式会社 メラニン生成抑制外用剤
DE4113984C2 (de) 1991-04-29 2002-05-08 Koehler Chemie Dr Franz Salze der 4-Hydroxy-Buttersäure
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
IT1248588B (it) 1991-06-28 1995-01-19 Gaetano Crepaldi Composizioni farmaceutiche per la terapia dell'astinenza, del " craving", della dipendenza da sostanze stupefacenti, da sostanze psicoattive, da nicotina e dei disturbi alimentari.
US5371424A (en) 1992-11-25 1994-12-06 Motorola, Inc. Transmitter/receiver circuit and method therefor
IT1271403B (it) 1993-03-26 1997-05-28 Ct Lab Farm Srl Sali dell'acido gamma-idrossibutirrico ad attivita' ansiolitica e per il trattamento degli stati depressivi
IT1266565B1 (it) * 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
US5840331A (en) * 1995-06-07 1998-11-24 Arch Development Corporation Use of γ-hydroxybutyrate for the stimulation of sleep-related secretion growth hormone and prolactin
US6077545A (en) 1995-10-30 2000-06-20 Matrix Pharmaceuticals, Inc. Process and composition for therapeutic cisplatin (CDDP)
DE19602664A1 (de) 1996-01-25 1997-08-07 Waltenberger Karl Hans Mittel zum Inhibieren des Algenwachstums
KR20050047560A (ko) 1996-04-05 2005-05-20 다께다 케미칼 인더스트리즈,리미티드 안지오텐신 ⅱ 및 길항 활성을 갖는 화합물을 함유하는약제학적 조합물
IT1283782B1 (it) 1996-08-09 1998-04-30 Ct Lab Farm Srl Uso di ammidi dell'acido gamma-idrossibutirrico nel trattamento di tossicodipendenze,ed in particolare sell'alcolismo
ES2241053T3 (es) 1996-08-15 2005-10-16 Schering Corporation Eteres antagonistas muscarinicos.
US20080292700A1 (en) 1997-04-21 2008-11-27 Biovail Laboratories Controlled release formulations using intelligent polymers
US5990162A (en) * 1997-08-29 1999-11-23 Orphan Medical, Inc. Method for treatment of fibromyalgia and chronic fatigue syndrome
WO2000038672A2 (en) 1998-12-23 2000-07-06 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy

Also Published As

Publication number Publication date
US6472431B2 (en) 2002-10-29
US6780889B2 (en) 2004-08-24
WO2000038672A3 (en) 2000-11-09
US9539330B2 (en) 2017-01-10
US20130143965A1 (en) 2013-06-06
US7851506B2 (en) 2010-12-14
US20070270491A1 (en) 2007-11-22
US20160058862A1 (en) 2016-03-03
US8461203B2 (en) 2013-06-11
EP1140061B1 (en) 2003-05-02
US8859619B2 (en) 2014-10-14
IL143733A (en) 2006-10-31
ES2193777T3 (es) 2003-11-01
US20150073052A1 (en) 2015-03-12
AU2059000A (en) 2000-07-31
US20190328882A1 (en) 2019-10-31
US8324275B2 (en) 2012-12-04
US7262219B2 (en) 2007-08-28
US20170224825A1 (en) 2017-08-10
JP2009167189A (ja) 2009-07-30
US20120202880A1 (en) 2012-08-09
US20120020833A1 (en) 2012-01-26
US20030125385A1 (en) 2003-07-03
DK1140061T3 (da) 2003-08-25
CA2355293A1 (en) 2000-07-06
CA2355293C (en) 2005-08-16
US20020077334A1 (en) 2002-06-20
US20110039929A1 (en) 2011-02-17
JP2002533388A (ja) 2002-10-08
ATE238783T1 (de) 2003-05-15
DE69907508T2 (de) 2003-11-20
JP5204685B2 (ja) 2013-06-05
WO2000038672A2 (en) 2000-07-06
US20130267595A1 (en) 2013-10-10
DE69907508D1 (de) 2003-06-05
US8952062B2 (en) 2015-02-10
US8263650B2 (en) 2012-09-11
JP4374441B2 (ja) 2009-12-02
AU779354B2 (en) 2005-01-20
US20040209955A1 (en) 2004-10-21
EP1140061A2 (en) 2001-10-10
US20120202879A1 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
IL143733A0 (en) Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
DE69528039D1 (de) Inhibitoren der fettsäuresynthese als antimikrobielle mittel
WO2000047255A8 (en) Method and apparatus for automatically controlling the level of medication
MXPA02007639A (es) Inhibidores de la oxidacion parcial de los acidos grasos en el tratamiento de la falla cardiaca congestiva.
BE2012C040I2 (ja)
PT867184E (pt) Utilizacao de tiagabina para o tratamento de desordens do sono
IL151164A0 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
WO2001056567A8 (en) 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors
WO2001043732A3 (en) Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
MXPA03000188A (es) Metodo de tratamiento de enfermedades relacionadas con neutroficos con anestesicos locales.
EP1952809A3 (en) Formulations for the reduction of breast density with 4-Hydroxy Tamoxifen
HK1047707A1 (zh) (+)-曲馬朵、o-去甲曲馬朵或(+)-o-去甲曲馬朵、o-去甲-n-單-去甲-曲馬朵或(+)-o-去甲-n-單-去甲-曲馬朵治療尿失禁的用途
WO1999015643A3 (en) ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO ANGIOTENSI N CONVERTING ENZYME mRNA AND METHODS OF USE
PT1261333E (pt) Utilizacao de topiramato para o tratamento e diagnostico de transtorno do sono relacionado com a respiracao e meios para realizar o metodo e o diagnostico
WO1998026770A3 (en) The topical use of kappa opioid agonists to treat ocular pain
NZ506681A (en) Disinfecting composition
WO2002005642A3 (en) Synergistic biocidal compositions
DE60013823D1 (de) Teilbare hüllenanordnung mit okklusionsballon
WO2000059940A3 (en) Platelet-derived growth factor related gene and protein
AU6846300A (en) Use of cyamemazine for cold turkey benzodiazepine treatment
WO2002067851A3 (en) Method for treating fibrotic diseases or other indications iiic
AU2976095A (en) Use of selegilin in the treatment of epileptic conditions
AUPP379698A0 (en) Using ngali nut oil to treat/relieve the pain of arthritis and other similar conditions
GB9500024D0 (en) Treatment of excessive cell proliferation disorders
BR0016720A (pt) Uso de trimebutina para tratamento de dores

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed